Objective To investigate the relationship between interleukin-1β (IL-1β) and miR-185-5p in the process of joint injury in acute gouty arthritis (AGA). Methods The serum miR-185-5p levels of 89 AGA patients and 91 healthy volunteers were detected by real-time quantitative PCR. The correlation between miR-185-5p expression level and VAS score or IL-1β expression level was evaluated by Pearson correlation coefficient method. Receiver operating characteristic (ROC) curve was used to evaluate the diagnostic value of miR-185-5p in AGA. THP-1 cells were induced by sodium urate (MSU) to construct an in vitro acute gouty inflammatory cell model. After the expression level of miR-185-5p in THP-1 cells was upregulated or downregulated by transfection of miR-185-5p mimics or inhibitors in vitro, inflammatory cytokines of THP-1 cells, such as IL-1β, IL-8 and tumor necrosis factor α (TNF-α), were detected by ELISA. The luciferase reporter gene assay was used to determine the interaction between miR-185-5p and the 3'-UTR of IL-1β. Results Compared with the healthy control group, the expression level of serum miR-185-5p in AGA patients was significantly reduced. The level of serum miR-185-5p was negatively correlated with VAS score and IL-1β expression level. The area under the curve (AUC) was 0.905, the sensitivity was 80.17% and the specificity was 83.52%. Down-regulation of miR-185-5p significantly promoted the expression of IL-1β, IL-8 and tumor necrosis factor (TNF-α), while overexpression of miR-185-5p showed the opposite results. Luciferase reporter gene assay showed that IL-1β was the target gene of miR-185-5p, and miR-185-5p negatively regulated the expression of IL-1β. Conclusion miR-185-5p alleviates the inflammatory response in AGA by inhibiting IL-1β.
Humans ; 3' Untranslated Regions ; Arthritis, Gouty/genetics* ; Interleukin-1beta/genetics* ; Interleukin-8 ; Luciferases ; MicroRNAs/genetics* ; Tumor Necrosis Factor-alpha

Objective To investigate the distribution characteristics of HIV-1 subtypes,the status of transmitted drug resistance(TDR),and the influencing factors of TDR in treatment-naive patients with AIDS who are hospitalized.Methods Treatment-naive patients with AIDS who were admitted to the Infectious Disease Department,Public Health Clinical Center of Chengdu between January 2020 and December 2022 were enrolled in the study.The diagnosis and confirmation diagnosis of all the subjects were made at the same hospital.Blood samples were collected from the subjects before antiretroviral therapy(ART).The in-house method was used for HIV gene amplification and sequencing.A phylogenetic tree was constructed to analyze the HIV-1 subtypes.The Stanford HIV Drug Resistance Database was used to conduct an online comparative analysis of the drug resistance mutation sites and to determine the types and levels of drug resistance.The distribution characteristics of HIV-1 subtypes,the occurrence of TDR,and the influencing factors of TDR were analyzed.Results A total of 213 patients were included in the study and their blood samples were collected.HIV-1 subtypes were successfully amplified in 83.10％(177/213)of the subjects.Ten HIV subtypes were identified,with CRF07_BC being the most common subtypes,accounting for 43.50％(77/177),which was followed by CRF01_AE at 37.85％.Unique recombinant forms(URFs)were relatively uncommon,accounting for 8.47％.The other subtypes accounted for 10.17％.These 4 categories of HIV-1 subtypes were distributed with statistically significant differences in different age groups(P=0.024).Further analysis revealed significant differences in the distribution of the HIV-1 subtypes of CRF01_AE and URFs between the groups of patients aged 30-50 years and those over 50.In addition,URFs accounted for a higher proportion in patients aged 30 to 50 years(P=0.008).The incidences of TDR were 6.49％,8.96％,13.33％,and 5.56％for CRF07_BC,CRF01_AE,URFs,and other subtypes,respectively,showing no significant difference(P＞0.05).The overall TDR was 6.57％.The TDR for non-nucleoside reverse transcriptase inhibitors(NNRTIs)was 5.16％,and the main mutation sites were V179D/E,E138A/G,V106M/I,and Y181C.The TDR for nucleoside reverse transcriptase inhibitors(NRTIs)was 1.88％,and the main mutation site was M184V.One patient was found to be resistant to both NNRTIs and NRTIs.The highly resistant rate was 4.23％,moderate resistance was 0.47％,and low resistance was 1.88％.No significant effects of the specific years,demographic characteristics,transmission route,baseline condition,and opportunistic infections on TDR were found in this study(P＞0.05).Conclusions The HIV-1 subtypes are diverse and complex in treatment-naive patients with AIDS who were hospitalized.The overall prevalence of TDR is relatively high.It is necessary to strengthen HIV drug resistance testing to optimize ART treatment and reduce the risk of drug resistance transmission.

Objective: To optimize the inclusion process of volatile oil in Xiao' er Jiegan particle.Methods: β-Cyclodextrin was used as the inclusion material.Orthogonal experiments were performed,and the yield of volatile oil inclusion complex and the inclusion rate of volatile oil were taken as the indices to study the influence of inclusion temperature, inclusion time and the ratio of β-cyclodextrin to volatile oil (g∶ml) on the inclusion process.The β-CD-volatile oil inclusion complex was added to Xiao' er Jiegan particle and the stability studies were conducted as well.Results: The optimum volatile oils inclusion process of Xiao'er Jiegan particle was as follows: the inclusion temperature was 40℃, the inclusion time was 3 h , and the ratio of β-cyclodextrin to volatile oil (g∶ml) was 8∶1.The loss of volatile oil prepared by direct injection method was 51.27% after 6-month storage at room temperature, while that prepared by the inclusion method was only 3.13% after 24-month storage at room temperature.Conclusion: The optimized inclusion process of volatile oil is reasonable and feasible, and the stability of the prepared particle is also promising.

Objective To explore the clinical effect and safety of using recombinant tissue type plasminogen activator (rt-PA) in early lower extremity deep venous thrombosis (DVT) after gynecological surgeries. Methods Twenty-five cases with early DVT after gynecological operation were enrolled and randomly divided into two groups,contorl group (n = 13) and the rt-PA therapy group (n = 12). The patients from contorl group were treated with Low-Molecular-Weight Heparins Calcium 0. 4 ml/d alone, and the rt-PA group accepted rt-PA 100 mg i. v in addition to the Low-Molecular-Weight Heparins Calcium. The recanalization rates of lamb veins,prothrombin time (PT) ,bleeding event and other adverse complications were observed and evaluated at day seven. Results The recanalization rates of lamb veins were 91. 7% (11/12) and 53. 8 % (7/13) in rtPA and the control group respectively,which showed significant difference between each other (x2 = 15. 68, P <0. 01). One case had vaginal stump bleeding in each group but no other hemorrhage in both group,the difference of bleeding rates between two groups didn't reach statistically significance (x2 = 1. 48 ,P> 0. 05). Two patients with vaginal stump bleeding were healed by local hemostasis. Conclusion The usage of rt-PA could improve the recanalization rate of DVT after gynecological surgery. The rates of adverse complications, including vaginal stump bleeding,were extremly low.